CoChat

Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases

Open access
Lynch, Joseph P., Clark, Nina M., Zhanel, George G. · 2021 · Expert Opinion on Pharmacotherapy

The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.

Abstract

Introduction: Over the past few decades, antimicrobial resistance (AMR) has skyrocketed globally among bacteria within the Family Enterobacteriaceae (i.e. Enterobacter spp, Klebsiella spp, Escherichia coli, Proteus spp, Serratia marcescens, Citrobacter spp, and others). Enterobacteriaceae are intestinal flora and are important pathogens in nosocomial and community settings. Enterobacteriaceae spread easily between humans and may acquire AMR via plasmids or other mobile resistance elements. The emergence and spread of multidrug resistant (MDR) clones have greatly limited therapeutic options. Some infections are untreatable with existing antimicrobials.Areas covered: The authors discuss the escalation of CRE globally, the epidemiology and outcomes of CRE infections, the optimal therapy, and the potential role of several new antimicrobials to combat MDR organisms. An exhaustive search for literature related to Enterobacteriaceae was performed using PubMed, using the following key words: antimicrobial resistance; carbapenemases; Enterobacterales; Enterobacteriaceae; Klebsiella pneumoniae; Escherichia coli; global epidemiology; metallo-β-lactamases; multidrug resistance; New Delhi Metalloproteinase-1 (NDM-1); plasmidsExpert opinion: Innovation and development of new classes of antibacterial agents are critical to expand effective therapeutic options. The authors encourage the judicious use of antibiotics and aggressive infection-control measures are essential to minimize the spread of AMR.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2021.1904891

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 205 references

Research works printed but not linked: 26

  1. Pitout JDD, Peirano G, Kock MM, et al. The Global Ascendency of OXA-48-Type Carbapenemases. Clin Microbiol Rev. 2019;33(1):e00102-19.
  2. 10.3390/medsci6010001 · DOI · Paper page
  3. Wu W, Feng Y, Tang G, et al. NDM Metallo-beta-Lactamases and their bacterial producers in health care settings. Clin Microbiol Rev. 2019;32(2);e00115-18.
  4. Iacchini S, Sabbatucci M, Gagliotti C, et al. Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017. Euro Surveill. 2019;24(5):1800159.
  5. Mataseje LF, Boyd DA, Mulvey MR, et al. Two Hypervirulent Klebsiella pneumoniae Isolates Producing a bla KPC-2 Carbapenemase from a Canadian patient. Antimicrob Agents Chemother. 2019;63(7):e00517-19.
  6. Aires-de-sousa M, Fournier C, Lopes E, et al. High colonization rate and heterogeneity of ESBL- and Carbapenemase-Producing Enterobacteriaceae Isolated from Gull Feces in Lisbon, Portugal. Microorganisms. 2020;8.
  7. 10.1080/1040841X.2020.1812510 · doi:10.1080/1040841x.2020.1812510
  8. Irrgang A, Tausch SH, Pauly N, et al. First Detection of GES-5-Producing Escherichia coli from Livestock-An Increasing Diversity of Carbapenemases recognized from German Pig Production. Microorganisms. 2020;8(10):1593.
  9. Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother. 2011;66(Suppl 6):vi3–12.
  10. Zhang Y, Wang Q, Yin Y, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2):e01882-17.
  11. Ara-Montojo MF, Escosa-Garcia L, Alguacil-Guillen M, et al. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. J Antimicrob Chemother. 2020;76(1):220-225.
  12. Litwin A, Fedorowicz O, Duszynska W. Characteristics of microbial factors of healthcare-associated infections including multidrug-resistant pathogens and antibiotic consumption at the university intensive care unit in Poland in the Years 2011-2018. Int J Environ Res Public Health. 2020;17(19):6943.
  13. Fournier S, Desenfant L, Monteil C, et al. Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015. Euro Surveill. 2018;23(8):17-00078.
  14. Gauthier L, Dortet L, Cotellon G, et al. Diversity of Carbapenemase-producing Escherichia coli isolates in France in 2012-2013. Antimicrob Agents Chemother. 2018;62(8):e00266-18.
  15. Brolund A, Lagerqvist N, Byfors S, et al. Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill. 2019;24(9):1900123.
  16. Falcone M, Giordano C, Barnini S, et al. Extremely drug-resistant NDM-9-producing ST147 Klebsiella pneumoniae causing infections in Italy, May 2020. Euro Surveill. 2020;25(48):2001779.
  17. Russo A, Giuliano S, Ceccarelli G, et al. Comparison of septic shock due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in intensive care unit patients. Antimicrob Agents Chemother. 2018;62(6):e02562-17.
  18. Walkty A, Karlowsky JA, Baxter MR, et al. In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study. Antimicrob Agents Chemother. 2019;63(1):e01832-18.
  19. Andrade FF, Silva D, Rodrigues A, et al. Colistin update on its mechanism of action and resistance, present and future challenges. Microorganisms. 2020;8(11):1716. DOI:10.3390
  20. Clark JA, Kulengowski B, Burgess DS. In-vitro activity of Eravacycline compared to Tigecycline and Carbapenem-resistant Enterobacteriaceae. Int J Antimicrob Agents. 2020;56(6):106178.
  21. Morrissey I, Olesky M, Hawser S, et al. In vitro activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020;22(5):556-561;64(3):e01699-19.
  22. 10.1089/sur.2020.241 · DOI
  23. Leelawattanachai P, Wattanavijitkul T, Paiboonvong T, et al. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation. Antibiotics (Basel). 2020;9(9):615.
  24. Ackley R, Roshdy D, Meredith J, et al. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2020.(5):e02313–19.
  25. Hackel MA, Tsuji M, Yamano Y, et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62:e0196817.
  26. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2020;21(2);226-240.

Cited by

See all 58

Metadata

Authors
Lynch, J. P., Clark, N. M., & Zhanel, G. G.
Affiliations
  • University of California, Los Angeles (US)
  • Loyola University Chicago (US)
  • University of Manitoba (CA)
Corresponding author
Lynch, Joseph P.
Venue
Expert Opinion on Pharmacotherapy
Published
2021-07-24
Volume
22
Issue
11
Pages
1455-1474
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W3142645707
Cited by
58
References
205
Citations by year
2026: 7 · 2025: 20 · 2024: 11 · 2023: 12 · 2022: 7 · 2021: 1
FWCI
2.46
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
manuscript was not
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
Keywords
antimicrobial resistance, Enterobacteriaceae, carbapenemase, carbapenem resistance, multidrug resistance, Klebsiella pneumoniae, Escherichia coli, metallo-beta-lactamase, NDM-1, plasmids, nosocomial infections, infection control, antibiotic stewardship, novel antibiotics
MeSH terms
Anti-Infective Agents, Anti-Bacterial Agents, Bacterial Proteins, beta-Lactamases, Enterobacteriaceae, Enterobacteriaceae Infections, Humans, Microbial Sensitivity Tests, Drug Resistance, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases. https://app.cochat.ai/papers/10.1080/14656566.2021.1904891
The paper
Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2021). Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2021.1904891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.